AbbVie’s portfolio of antibodies for the potential treatment of idiopathic pulmonary fibrosis (IPF) now includes DJS-002 — a first-in-class antibody…
Articles by Patricia Inácio, PhD
BenevolentAI has identified a new treatment target for idiopathic pulmonary fibrosis (IPF) that will be added to…
Algernon Pharmaceuticals’ experimental oral therapy NP-120 (ifenprodil) significantly reduced coughing in people with idiopathic pulmonary fibrosis (IPF), according…
A total of 30 patient advocacy groups working to further understanding and the needs of people living with rare diseases…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Tvardi Therapeutics’ TTI-101 for the treatment of…
Abnormally high levels of the signaling molecule interleukin 19 (IL-19) were detected in lung tissues from both mice and humans…
Supplementary oxygen using a high‐flow nasal cannula boosts exercise endurance more effectively than standard devices in idiopathic pulmonary fibrosis…
In commemoration of the International Quality of Life Month happening in January, the Pulmonary Fibrosis Foundation (PFF) is calling…
The first patient has been enrolled in a pivotal Phase 2b trial investigating the safety and effectiveness of Horizon…
PF Warriors has partnered with online shopping site Joe & Bella to make holiday gift-giving easier for people with…